Gwang-Seong Choi, Woo-Young Sim, Hoon Kang, Chang Hun Huh, Yang Won Lee, Sumitra Shantakumar, Yu-Fan Ho, Eun-Jeong Oh, Mei Sheng Duh, Wendy Y Cheng, Priyanka Bobbili, Philippe Thompson-Leduc, Gary Ong
{"title":"杜他雄胺与非那雄胺在韩国男性雄激素性脱发患者中的长期有效性和安全性:一项多中心图表回顾研究。","authors":"Gwang-Seong Choi, Woo-Young Sim, Hoon Kang, Chang Hun Huh, Yang Won Lee, Sumitra Shantakumar, Yu-Fan Ho, Eun-Jeong Oh, Mei Sheng Duh, Wendy Y Cheng, Priyanka Bobbili, Philippe Thompson-Leduc, Gary Ong","doi":"10.5021/ad.22.027","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Dutasteride improves hair growth compared with finasteride in male androgenic alopecia (AGA) and is well tolerated. However, real-world evidence for long-term dutasteride use in AGA is lacking.</p><p><strong>Objective: </strong>To describe baseline characteristics, treatment patterns and long-term safety and effectiveness of dutasteride versus finasteride.</p><p><strong>Methods: </strong>This was a multicentre, retrospective medical chart review study conducted in South Korea. The index date was the first prescription of dutasteride or finasteride. Baseline characteristics were assessed 6 months prior to index. Safety and effectiveness (improvements in basic and specific [BASP] classification) data were collected from index throughout the observation period.</p><p><strong>Results: </strong>Overall, 600 male adult patients were included (dutasteride, n=295; finasteride, n=305). Dutasteride-treated patients were older (<i>p</i><0.001) and more likely to have moderate/severe BASP classification at baseline (<i>p</i>=0.010) compared with finasteride-treated patients. Among patients treated with recommended, on-label dosing exclusively (n=535: dutasteride, n=250; finasteride, n=285), dutasteride-treated patients showed greater improvement in hair growth than finasteride-treated patients, as measured by the BASP basic M classification (adjusted incidence rate ratio [95% confidence interval]: 2.06 [1.08, 3.95]; <i>p</i>=0.029). Among this same subset, overall occurrence of adverse events (AEs) during the observation period were not statistically equivalent between groups (dutasteride 7.6%, finasteride 10.5%; <i>p</i>=0.201), although reports of AEs of special interest were equivalent (<i>p</i><0.001).</p><p><strong>Conclusion: </strong>Dutasteride showed greater effectiveness than finasteride in improving BASP classification in treating male AGA and had a similar or possibly lower occurrence of overall AEs. Dutasteride may provide an effective and safe treatment option for male patients with AGA.</p>","PeriodicalId":8233,"journal":{"name":"Annals of Dermatology","volume":"34 5","pages":"349-359"},"PeriodicalIF":1.5000,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/85/a8/ad-34-349.PMC9561294.pdf","citationCount":"3","resultStr":"{\"title\":\"Long-Term Effectiveness and Safety of Dutasteride versus Finasteride in Patients with Male Androgenic Alopecia in South Korea: A Multicentre Chart Review Study.\",\"authors\":\"Gwang-Seong Choi, Woo-Young Sim, Hoon Kang, Chang Hun Huh, Yang Won Lee, Sumitra Shantakumar, Yu-Fan Ho, Eun-Jeong Oh, Mei Sheng Duh, Wendy Y Cheng, Priyanka Bobbili, Philippe Thompson-Leduc, Gary Ong\",\"doi\":\"10.5021/ad.22.027\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Dutasteride improves hair growth compared with finasteride in male androgenic alopecia (AGA) and is well tolerated. However, real-world evidence for long-term dutasteride use in AGA is lacking.</p><p><strong>Objective: </strong>To describe baseline characteristics, treatment patterns and long-term safety and effectiveness of dutasteride versus finasteride.</p><p><strong>Methods: </strong>This was a multicentre, retrospective medical chart review study conducted in South Korea. The index date was the first prescription of dutasteride or finasteride. Baseline characteristics were assessed 6 months prior to index. Safety and effectiveness (improvements in basic and specific [BASP] classification) data were collected from index throughout the observation period.</p><p><strong>Results: </strong>Overall, 600 male adult patients were included (dutasteride, n=295; finasteride, n=305). Dutasteride-treated patients were older (<i>p</i><0.001) and more likely to have moderate/severe BASP classification at baseline (<i>p</i>=0.010) compared with finasteride-treated patients. Among patients treated with recommended, on-label dosing exclusively (n=535: dutasteride, n=250; finasteride, n=285), dutasteride-treated patients showed greater improvement in hair growth than finasteride-treated patients, as measured by the BASP basic M classification (adjusted incidence rate ratio [95% confidence interval]: 2.06 [1.08, 3.95]; <i>p</i>=0.029). Among this same subset, overall occurrence of adverse events (AEs) during the observation period were not statistically equivalent between groups (dutasteride 7.6%, finasteride 10.5%; <i>p</i>=0.201), although reports of AEs of special interest were equivalent (<i>p</i><0.001).</p><p><strong>Conclusion: </strong>Dutasteride showed greater effectiveness than finasteride in improving BASP classification in treating male AGA and had a similar or possibly lower occurrence of overall AEs. Dutasteride may provide an effective and safe treatment option for male patients with AGA.</p>\",\"PeriodicalId\":8233,\"journal\":{\"name\":\"Annals of Dermatology\",\"volume\":\"34 5\",\"pages\":\"349-359\"},\"PeriodicalIF\":1.5000,\"publicationDate\":\"2022-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/85/a8/ad-34-349.PMC9561294.pdf\",\"citationCount\":\"3\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Annals of Dermatology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.5021/ad.22.027\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"DERMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Dermatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5021/ad.22.027","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"DERMATOLOGY","Score":null,"Total":0}
Long-Term Effectiveness and Safety of Dutasteride versus Finasteride in Patients with Male Androgenic Alopecia in South Korea: A Multicentre Chart Review Study.
Background: Dutasteride improves hair growth compared with finasteride in male androgenic alopecia (AGA) and is well tolerated. However, real-world evidence for long-term dutasteride use in AGA is lacking.
Objective: To describe baseline characteristics, treatment patterns and long-term safety and effectiveness of dutasteride versus finasteride.
Methods: This was a multicentre, retrospective medical chart review study conducted in South Korea. The index date was the first prescription of dutasteride or finasteride. Baseline characteristics were assessed 6 months prior to index. Safety and effectiveness (improvements in basic and specific [BASP] classification) data were collected from index throughout the observation period.
Results: Overall, 600 male adult patients were included (dutasteride, n=295; finasteride, n=305). Dutasteride-treated patients were older (p<0.001) and more likely to have moderate/severe BASP classification at baseline (p=0.010) compared with finasteride-treated patients. Among patients treated with recommended, on-label dosing exclusively (n=535: dutasteride, n=250; finasteride, n=285), dutasteride-treated patients showed greater improvement in hair growth than finasteride-treated patients, as measured by the BASP basic M classification (adjusted incidence rate ratio [95% confidence interval]: 2.06 [1.08, 3.95]; p=0.029). Among this same subset, overall occurrence of adverse events (AEs) during the observation period were not statistically equivalent between groups (dutasteride 7.6%, finasteride 10.5%; p=0.201), although reports of AEs of special interest were equivalent (p<0.001).
Conclusion: Dutasteride showed greater effectiveness than finasteride in improving BASP classification in treating male AGA and had a similar or possibly lower occurrence of overall AEs. Dutasteride may provide an effective and safe treatment option for male patients with AGA.
期刊介绍：
Annals of Dermatology (Ann Dermatol) is the official peer-reviewed publication of the Korean Dermatological Association and the Korean Society for Investigative Dermatology. Since 1989, Ann Dermatol has contributed as a platform for communicating the latest research outcome and recent trend of dermatology in Korea and all over the world.
Ann Dermatol seeks for ameliorated understanding of skin and skin-related disease for clinicians and researchers. Ann Dermatol deals with diverse skin-related topics from laboratory investigations to clinical outcomes and invites review articles, original articles, case reports, brief reports and items of correspondence. Ann Dermatol is interested in contributions from all countries in which good and advanced research is carried out. Ann Dermatol willingly recruits well-organized and significant manuscripts with proper scope throughout the world.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
